Wary pharma: AstraZeneca sours on UK

Recessions are, in their way, bad news. But so, paradoxically, is a lasting dearth of them. We explain the dangers that lie beneath the current run of continuous growth. Our correspondent looks into the hidden economics of online reviews, and whether to trust them. And a turkey-i ...  Afficher plus

In a world of infinite content, who wins and who loses? Our correspondent explains what the proliferation of AI-generated art means for human artists. What the prevalence of male-female friendships tell us about a society. And why you should propose with a yellow-gold ring. Liste ...  Afficher plus

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Afficher plus

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Afficher plus

With China as its new rival, America is reviving old wartime facilities across the Pacific. Our correspondent visits an abandoned airfield that has been given new life. The outlook for climate technology is surprisingly bright. And why the universe of Hello Kitty keeps expanding. ...  Afficher plus

Since Donald Trump announced punishing tariffs on “Liberation Day” last week, stock markets have fallen and governments and businesses scrambled to respond. Our correspondent discusses the impact on the global economy. Do personalised diets really improve gut health (9:16)? And g ...  Afficher plus